Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL From the CLL2-BAAG Trial"

61 views
December 29, 2023
Comments 0
Login to view comments. Click here to Login